Publications

Journal Article
Research Support, Non-U.S. Gov't
Ppublish
Electronic publication date
January 20, 2025

View on Pubmed.gov 39831520 | View on doi.org 10.1080/2150559...

Immunogenicity and vaccine efficacy of Actinobacillus pleuropneumoniae-derived extracellular vesicles as a novel vaccine candidate.

Search for publications in this journal Virulence - 16(1):2453818

  • Su Hyun Park

    Search for this expert
    1
  • Yun Hye Kim 2 3
  • Hyeon Jin Lee

    Search for this expert
    4
  • Jeong Moo Han

    Search for this expert
    5
  • Byoung-Joo Seo

    Search for this expert
    6
  • Gyeong-Seo Park

    Search for this expert
    6
  • Chonghan Kim

    Search for this expert
    6
  • Young Bae Ryu

    Search for this expert
    2
  • Woo Sik Kim

    Search for this expert
    2

Abstract

Actinobacillus pleuropneumoniae (APP) is a significant pathogen in the swine industry, leading to substantial economic losses and highlighting the need for effective vaccines. This study evaluates the potential of APP-derived extracellular vesicles (APP-EVs) as a vaccine candidate compared to the commercial Coglapix vaccine. APP-EVs, isolated using tangential flow filtration (TFF) and cushioned ultracentrifugation, exhibited an average size of 105 nm and a zeta potential of -17.4 mV. These EVs demonstrated stability under external stressors, such as pH changes and enzymatic exposure and were found to contain 86 major metabolites. Additionally, APP-EVs induced dendritic cell (DC) maturation in a Toll-like receptor 4 (TLR4)-dependent manner without cytotoxicity. APP-EVs predominantly elicited Th1-mediated IgG responses in immunized mice without significant liver and kidney toxicity. Contrarily, unlike Coglapix, which induced stronger Th2-mediated responses and notable toxicity. In addition, APP-EVs triggered APP-specific Th1, Th17, and cytotoxic T lymphocyte (CTL) responses and promoted the activation of multifunctional T-cells. Notably, APP-EV immunization enhanced macrophage phagocytosis and improved survival rates in mice challenged with APP infection compared to those treated with Coglapix. These findings suggest that APP-EVs are promising vaccine candidates, capable of inducing potent APP-specific T-cell responses, particularly Th1, Th17, CTL, and multifunctional T-cells, thereby enhancing the protective immune response against APP infection.

References

Antibiotics (Basel). 2023 Aug 08;12(8):

Pathogens. 2024 May 15;13(5):

J Transl Med. 2021 May 11;19(1):202

Nat Rev Immunol. 2002 Jun;2(6):401-9

Cited by

Journal Article Review

Nanomaterial Adjuvants for Veterinary Vaccines: Mechanisms and Applications.

Electronic publication date July 10, 2025

Search for publications in this journal Research (Wash D C)

Li He [...] Yuli Li et al.

Safe and effective veterinary vaccines prevent infectious diseases and reduce morbidity. In this field, nanovaccines based on nanomaterials are emerging,...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances